标题：Repeated sub-chronic oral toxicity study of xylooligosaccharides (XOS) in dogs
作者：Gao, Yonglin; Wang, Yunzhi; Li, Yanshen; Han, Rui; Li, Chunmei; Xiao, Lin; Cho, Susan; Ma, Yukui; Fang, Chao; Lee, Albert W.
作者机构：[Gao, Yonglin; Wang, Yunzhi; Li, Yanshen] Yantai Univ, Sch Life Sci, Yantai 264005, Peoples R China.; [Han, Rui; Li, Chunmei] Yantai Univ, Collabora 更多
通讯作者地址：[Lee, AW]NutraSource Inc, Royal Oak, MI 48073 USA.
来源：REGULATORY TOXICOLOGY AND PHARMACOLOGY
关键词：Xylooligosaccharide; Subchronic toxicity; Beagle dog
摘要：In this study, Beagle dogs were administered xylooligosaccharide (XOS, CAS # 87099-0) at doses of 0, 1250, 2500, and 5000 mg/kg/day by oral gavage for 26 weeks. A 4-week recovery period was added to observe delayed or reversible toxicity. Measurements included body weight, food consumption, clinical observations, temperature, electrocardiogram (ECG), urinalysis, blood chemistry, hematology, organ weight, gross necropsy, and histopathological examination. Except for transient diarrhea or vomiting, no treatment-related adverse effects were noted. In the mid-dose groups, transitional diarrhea was observed in the initial 1-2 weeks. In the high-dose groups, diarrhea and/or vomiting were observed episodically over the duration of treatment. However, they disappeared after XOS was withdrawn in the recovery period. Although there was a tendency toward less weight gain in the high-dose group animal group, this is typical in animals and humans fed non-digestible carbohydrates. This chronic toxicity study demonstrated that the no observed adverse effect level (NOAEL) of XOS is 2500 mg/kg body weight (BW)/day. Based on body surface area (conversion factor of 0.54 for dogs to human), this corresponds to daily doses of 1350 mg/kg BW or 81-108 g XOS in human adults weighing 60-80 kg. (C) 2017 Published by Elsevier Inc.